



October 30, 2015

Press release

Mitsubishi Tanabe Pharma Corporation

**Medicago Engaged by the Canadian Government**  
**Produce Ebola Monoclonal Antibodies**

**Osaka, Japan, October 30, 2015**—Mitsubishi Tanabe Pharma Corporation (President and Representative Director: Masayuki Mitsuka) has announced Medicago Inc., (Head Office: Quebec, Canada; President and CEO: Andy Sheldon), its consolidated subsidiary, signed a contract with the Public Health Agency of Canada (PHAC), the institution in the Canadian government. The contract is for producing two antibodies to fight the Sudan strain of Ebola virus.

Resulting in the Ebola hemorrhagic fever (Zaire strain) that was mass infection in the last year in West Africa, Medicago signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), a public institution within the U.S. Department of Health and Human Services in February, 2015. Under the contract, Medicago has developed of production process for Ebola antibodies (Zaire strain) that is used with Medicago's innovative technology, plant-based protein production, extraction and refining.

On the basis of the contract signed with the Canadian government, in preparation for the outbreak of future Ebola hemorrhagic fever, Medicago will produce Ebola antibodies (Sudan strain) and provide to PHAC to the target in July 2016.

In addition, Ebola hemorrhagic fever caused by Sudan strains became large outbreak in Africa in 1976 and 2000.

“Medicago will be using its technology and manufacturing system to collaborate with the Canadian government to provide a solution for the possible re-emergence of this devastating disease. We are also proud to work on a Canadian solution that can be employed as a response to other biological threats that may impact national and international security in the future”, Andy Sheldon said.

((For Details, Contact the Following Section))  
Corporate Communications Department  
Tel +81-6-6205-5211